SCHEMBL26060197

SCHEMBL26060197

CCC1(CCCCc2ccc(CCCCC(C)(C)CC(=O)O)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.45
CPT2 P23786 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 3/20 0.39
OPRM1 P35372 1/20 0.38
OPRL1 P41146 1/20 0.38
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37
SLC13A5 Q86YT5 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
S1PR1 P21453 3/20 0.36
S1PR4 O95977 1/20 0.36
S1PR3 Q99500 1/20 0.36
S1PR5 Q9H228 1/20 0.36
RARB P10826 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25358147 0.90 FFAR1 (0.45) FFAR1CPT2TDP1ALDH1A1OPRM1
SCHEMBL25995660 0.83 FFAR1 (0.39) FFAR1CPT2TDP1ALDH1A1OPRM1
SCHEMBL25353036 0.83 FFAR1 (0.64) FFAR1CPT2TDP1ALDH1A1HPGD
SCHEMBL26060198 0.82 ALDH1A1 (0.39) ALDH1A1OPRM1OPRL1HPGDHSD17B10
SCHEMBL26060203 0.81 ALDH1A1 (0.45) ALDH1A1OPRM1OPRL1HPGDHSD17B10
SCHEMBL30549467 0.81 FFAR1 (0.41) FFAR1CPT2TDP1ALDH1A1OPRM1
SCHEMBL25352790 0.81 FFAR1 (0.41) FFAR1CPT2TDP1ALDH1A1OPRM1
SCHEMBL26060195 0.81 FFAR1 (0.56) FFAR1CPT2TDP1ALDH1A1HPGD
SCHEMBL25995695 0.78 FFAR1 (0.43) FFAR1CPT2TDP1OPRM1OPRL1
SCHEMBL10268439 0.77 FFAR1 (0.45) FFAR1CPT2TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2023-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease AHR, PKD1, CFTR FFAR1 68/4885CPT2 615/4885TDP1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.